Cargando…

Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)

BACKGROUND: Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high. Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lun...

Descripción completa

Detalles Bibliográficos
Autores principales: van Teeffelen, Augustinus S P, van der Ham, David P, Willekes, Christine, Al Nasiry, Salwan, Nijhuis, Jan G, van Kuijk, Sander, Schuyt, Ewoud, Mulder, Twan L M, Franssen, Maureen T M, Oepkes, Dick, Jansen, Fenna A R, Woiski, Mallory D, Bekker, Mireille N, Bax, Caroline J, Porath, Martina M, de Laat, Monique W M, Mol, Ben W, Pajkrt, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997228/
https://www.ncbi.nlm.nih.gov/pubmed/24708702
http://dx.doi.org/10.1186/1471-2393-14-128
_version_ 1782313160491925504
author van Teeffelen, Augustinus S P
van der Ham, David P
Willekes, Christine
Al Nasiry, Salwan
Nijhuis, Jan G
van Kuijk, Sander
Schuyt, Ewoud
Mulder, Twan L M
Franssen, Maureen T M
Oepkes, Dick
Jansen, Fenna A R
Woiski, Mallory D
Bekker, Mireille N
Bax, Caroline J
Porath, Martina M
de Laat, Monique W M
Mol, Ben W
Pajkrt, Eva
author_facet van Teeffelen, Augustinus S P
van der Ham, David P
Willekes, Christine
Al Nasiry, Salwan
Nijhuis, Jan G
van Kuijk, Sander
Schuyt, Ewoud
Mulder, Twan L M
Franssen, Maureen T M
Oepkes, Dick
Jansen, Fenna A R
Woiski, Mallory D
Bekker, Mireille N
Bax, Caroline J
Porath, Martina M
de Laat, Monique W M
Mol, Ben W
Pajkrt, Eva
author_sort van Teeffelen, Augustinus S P
collection PubMed
description BACKGROUND: Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high. Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lung development. Repeated transabdominal amnioinfusion with the objective to alleviate oligohydramnios might prevent this complication and might improve neonatal outcome. METHODS/DESIGN: Women with PPROM and persisting oligohydramnios between 16 and 24 weeks gestational age will be asked to participate in a multi-centre randomised controlled trial. Intervention: random allocation to (repeated) abdominal amnioinfusion (intervention) or expectant management (control). The primary outcome is perinatal mortality. Secondary outcomes are lethal pulmonary hypoplasia, non-lethal pulmonary hypoplasia, survival till discharge from NICU, neonatal mortality, chronic lung disease (CLD), number of days ventilatory support, necrotizing enterocolitis (NEC), periventricular leucomalacia (PVL) more than grade I, severe intraventricular hemorrhage (IVH) more than grade II, proven neonatal sepsis, gestational age at delivery, time to delivery, indication for delivery, successful amnioinfusion, placental abruption, cord prolapse, chorioamnionitis, fetal trauma due to puncture. The study will be evaluated according to intention to treat. To show a decrease in perinatal mortality from 70% to 35%, we need to randomise two groups of 28 women (two sided test, β-error 0.2 and α-error 0.05). DISCUSSION: This study will answer the question if (repeated) abdominal amnioinfusion after midtrimester PPROM with associated oligohydramnios improves perinatal survival and prevents pulmonary hypoplasia and other neonatal morbidities. Moreover, it will assess the risks associated with this procedure. TRIAL REGISTRATION: NTR3492 Dutch Trial Register (http://www.trialregister.nl).
format Online
Article
Text
id pubmed-3997228
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39972282014-04-24 Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial) van Teeffelen, Augustinus S P van der Ham, David P Willekes, Christine Al Nasiry, Salwan Nijhuis, Jan G van Kuijk, Sander Schuyt, Ewoud Mulder, Twan L M Franssen, Maureen T M Oepkes, Dick Jansen, Fenna A R Woiski, Mallory D Bekker, Mireille N Bax, Caroline J Porath, Martina M de Laat, Monique W M Mol, Ben W Pajkrt, Eva BMC Pregnancy Childbirth Study Protocol BACKGROUND: Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high. Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lung development. Repeated transabdominal amnioinfusion with the objective to alleviate oligohydramnios might prevent this complication and might improve neonatal outcome. METHODS/DESIGN: Women with PPROM and persisting oligohydramnios between 16 and 24 weeks gestational age will be asked to participate in a multi-centre randomised controlled trial. Intervention: random allocation to (repeated) abdominal amnioinfusion (intervention) or expectant management (control). The primary outcome is perinatal mortality. Secondary outcomes are lethal pulmonary hypoplasia, non-lethal pulmonary hypoplasia, survival till discharge from NICU, neonatal mortality, chronic lung disease (CLD), number of days ventilatory support, necrotizing enterocolitis (NEC), periventricular leucomalacia (PVL) more than grade I, severe intraventricular hemorrhage (IVH) more than grade II, proven neonatal sepsis, gestational age at delivery, time to delivery, indication for delivery, successful amnioinfusion, placental abruption, cord prolapse, chorioamnionitis, fetal trauma due to puncture. The study will be evaluated according to intention to treat. To show a decrease in perinatal mortality from 70% to 35%, we need to randomise two groups of 28 women (two sided test, β-error 0.2 and α-error 0.05). DISCUSSION: This study will answer the question if (repeated) abdominal amnioinfusion after midtrimester PPROM with associated oligohydramnios improves perinatal survival and prevents pulmonary hypoplasia and other neonatal morbidities. Moreover, it will assess the risks associated with this procedure. TRIAL REGISTRATION: NTR3492 Dutch Trial Register (http://www.trialregister.nl). BioMed Central 2014-04-04 /pmc/articles/PMC3997228/ /pubmed/24708702 http://dx.doi.org/10.1186/1471-2393-14-128 Text en Copyright © 2014 van Teeffelen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Study Protocol
van Teeffelen, Augustinus S P
van der Ham, David P
Willekes, Christine
Al Nasiry, Salwan
Nijhuis, Jan G
van Kuijk, Sander
Schuyt, Ewoud
Mulder, Twan L M
Franssen, Maureen T M
Oepkes, Dick
Jansen, Fenna A R
Woiski, Mallory D
Bekker, Mireille N
Bax, Caroline J
Porath, Martina M
de Laat, Monique W M
Mol, Ben W
Pajkrt, Eva
Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title_full Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title_fullStr Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title_full_unstemmed Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title_short Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial)
title_sort midtrimester preterm prelabour rupture of membranes (pprom): expectant management or amnioinfusion for improving perinatal outcomes (ppromexil – iii trial)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997228/
https://www.ncbi.nlm.nih.gov/pubmed/24708702
http://dx.doi.org/10.1186/1471-2393-14-128
work_keys_str_mv AT vanteeffelenaugustinussp midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT vanderhamdavidp midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT willekeschristine midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT alnasirysalwan midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT nijhuisjang midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT vankuijksander midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT schuytewoud midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT muldertwanlm midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT franssenmaureentm midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT oepkesdick midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT jansenfennaar midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT woiskimalloryd midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT bekkermireillen midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT baxcarolinej midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT porathmartinam midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT delaatmoniquewm midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT molbenw midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial
AT pajkrteva midtrimesterpretermprelabourruptureofmembranesppromexpectantmanagementoramnioinfusionforimprovingperinataloutcomesppromexiliiitrial